Abstract
Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyses the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis. MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins. Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action. This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage φX174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate co-substrate. The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY. The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.
Keywords: Peptidoglycan biosynthesis, antibacterial agents, MraY, high-throughput screening
Infectious Disorders - Drug Targets
Title: Phospho-MurNAc-Pentapeptide Translocase (MraY) as a Target for Antibacterial Agents and Antibacterial Proteins
Volume: 6 Issue: 2
Author(s): Timothy D.H. Bugg, Adrian J. Lloyd and David I. Roper
Affiliation:
Keywords: Peptidoglycan biosynthesis, antibacterial agents, MraY, high-throughput screening
Abstract: Phospho-MurNAc-pentapeptide translocase (MraY, translocase I) catalyses the first step of the lipid-linked cycle of reactions of bacterial peptidoglycan biosynthesis. MraY is the target for five families of nucleoside antibacterial natural products: the tunicamycins, the mureidomycins (also pacidamycins, napsamycins), the liposidomycins, the muraymycins, and the capuramycins. Recent structure-activity studies on these families have led to the identification of active pharmacophores, and insight into their mechanisms of action. This step of peptidoglycan biosynthesis is also the target for the bacteriolytic E protein from bacteriophage φX174, and for cyclic peptides of the amphomycin family which complex the undecaprenyl phosphate co-substrate. The mechanisms of enzyme inhibition by these agents are discussed, and the state of knowledge regarding the transmembrane structure, active site, and catalytic mechanism of MraY. The availability of high throughput assays and prospects of MraY as an antibacterial target are also discussed.
Export Options
About this article
Cite this article as:
Bugg D.H. Timothy, Lloyd J. Adrian and Roper I. David, Phospho-MurNAc-Pentapeptide Translocase (MraY) as a Target for Antibacterial Agents and Antibacterial Proteins, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112128
DOI https://dx.doi.org/10.2174/187152606784112128 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cheminformatics Based Machine Learning Approaches for Assessing Glycolytic Pathway Antagonists of Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening In silico Analysis of Several Signal Peptides for the Excretory Production of Reteplase in Escherichia coli
Current Proteomics Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy
Recent Patents on Anti-Infective Drug Discovery Discovery of Anticancer Agents from 2-Pyrazoline-Based Compounds
Current Medicinal Chemistry An Overview of the Selectivity and Efficiency of the Bacterial Carbonic Anhydrase Inhibitors
Current Medicinal Chemistry Controlled Delivery of Biotechnological Products
Current Pharmaceutical Biotechnology Pharmacophore Modeling Methods in Focused Library Selection – Applications in the Context of a New Classification Scheme
Combinatorial Chemistry & High Throughput Screening Tumor Necrosis Factor Inhibitors in Pediatric Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Insights into Sepsis: What have we Learned and How will it Help?
Current Pharmaceutical Design 4-Mer Hyaluronan Oligosaccharides Stimulate Inflammation Response in Synovial Fibroblasts in Part via TAK-1 and in Part via p38-MAPK
Current Medicinal Chemistry Population Pharmacokinetics and its Role in Anti-Tuberculosis Drug Development and Optimization of Treatment
Current Pharmaceutical Design Biotechnology in the Development of New Vaccines and Diagnostic Reagents Against Tuberculosis
Current Pharmaceutical Biotechnology Comprehensive Evaluation and Clinical Application of Combined Redox Assay Methods to Determine Total Antioxidant Capacity
Current Analytical Chemistry Docking Studies for Multi-Target Drugs
Current Drug Targets Genomics and the Prospects for the Discovery of New Targets for Antibacterial and Antifungal Agents
Current Pharmaceutical Design Aiming at New Targets for the Treatment of Affective Disorders: An Introduction
Current Drug Targets New Insights in Design and Development of Antitubercular Drugs
Current Bioactive Compounds Machine Learning and Tubercular Drug Target Recognition
Current Pharmaceutical Design Mechanism of Actions of Non Peptide Antigens Activating Human Vγ9 / Vδ2 T Lymphocytes and their Potential Use for Immunointervention
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Management of Pleural Effusions in the Emergency Department
Reviews on Recent Clinical Trials